Clinical Trial Update: Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin [Phase 2]

View source ↗

Summary

Phase 2 trial update on abrocitinib showing efficacy in reducing pruritus in adults with prurigo nodularis and chronic pruritus of unknown origin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis
• Pruritus of Unknown Origin

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Johns Hopkins University | Conditions: Prurigo Nodularis, Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03